Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serlopitant for Pruritus in Epidermolysis Bullosa
NCT03836001Phase 2Completed
- Sponsor
- Stanford University
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epidermolysis bullosa (EB) comparing Placebo Arm with Serlopitant Arm (2 arms). Primary endpoint: Number of Patients Who Achieve at Least a 3-point Reduction in 24-hour Average Itch Numeric Rating Scale at 2 months. Started Apr 2019; status: completed.
02
Drugs
serlopitant
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT03836001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836001.